Glioblastoma invasion factor ODZ1 is induced by microenvironmental signals through activation of a Stat3-dependent transcriptional pathway

Veronica Vidal¹, Olga Gutiérrez¹, Ana Talamillo¹, Carlos Velasquez² & Jose L. Fernandez-Luna¹*

We have previously shown that the transmembrane protein ODZ1 serves for glioblastoma (GBM) cells to invade the surrounding tissue through activation of RhoA/ROCK pathway. However, the transcriptional machinery used by GBM cells to regulate the expression of ODZ1 is unknown. Here we show that interaction with tumor microenvironment elements, mainly activated monocytes through IL-6 secretion, and the extracellular matrix protein fibronectin, induces the Stat3 transcriptional pathway and upregulates ODZ1 which results in GBM cell migration. This signaling route is abrogated by blocking the IL-6 receptor, inhibiting Jak kinases or knocking down Stat3. Furthermore, we have identified a Stat3 responsive element in the ODZ1 gene promoter, about 1 kb from the transcription start site. Luciferase-reporter assays confirmed that the promoter responds to the presence of monocyctic cells and this activation is greatly reduced when the Stat3 site is mutated or following treatment with a neutralizing anti-IL-6 receptor antibody or transfecting GBM cells with a dominant negative variant of Stat3. Overall, we show that monocyte-secreted IL-6 and the extracellular matrix protein fibronectin activate the axis Stat3-ODZ1 and promote migration of GBM cells. This is the first described transcriptional mechanism used by tumor cells to promote the expression of the invasion factor ODZ1.

ODZ1 belongs to a family of large transmembrane proteins that have been mainly associated with embryonal development of the central nervous system¹. Recently, we described the expression of ODZ1 in glioblastoma (GBM) primary cells derived from surgical specimens² and showed that overexpression of the full length protein or the intracellular domain increased the invasion capacity of these tumor cells both in vitro and in vivo. Consistently, blockade of ODZ1 by deleting the intracellular domain or knocking down its expression drastically reduced invasiveness of GBM cells. ODZ1 has been related to different tumors, including B3 thymoma, through a chromosomal translocation involving exon 2 of C11orf73 and intron 19 of ODZ1. The fusion transcript is supposed to trigger nonsense-mediated decay resulting in mRNA degradation³, although no experimental confirmation was presented. ODZ1 has also been located close to the integration site of hepatitis B virus into the genome of hepatocellular carcinoma⁴ but functional consequences of this gene fusion have not been explored. Finally, a naturally occurring deletion of the entire ODZ1 gene has been described in a patient with GBM⁵. Tumor cells derived from this patient have a deficiency in cytoskeletal organization. Therefore, they are unable to form actin-dependent protrusions and have lower migration and invasion capacities. Invasiveness is a key hallmark of GBM hindering effective therapy and causing tumor recurrence, generally in close proximity to the original tumor site⁶. However, attempts to target the mechanisms involved in GBM invasiveness including cytoskeletal reorganization, cell migration and degradation of the extracellular matrix have not been translated into useful therapeutic strategies thus far⁷. One way to widen the options of therapeutic intervention is to fully understand the interactions between GBM cells and their microenvironment, including immune cells, secreted...
cytokines or growth factors and molecules of the extracellular matrix. Among the immune cells, bone marrow-derived marophages and resident microglia represent an important cell population comprising 30–50% of all cells in GBM tumors. These cells secrete a number of cytokines and chemokines that may be used by GBM cells to promote cell growth, invasion or immunosuppression through activation of intracellular pathways. To this end, one of the main signaling mediators in tumor cells is Stat3, which is involved in driving cell survival, proliferation, invasion and metastasis among other activities and this transcription factor is typically activated by triggering growth factor and cytokine receptors. Recently, it has been established a gene signature that stratifies GBM patients into Stat3-high and Stat3-low cohorts and showed that inhibition of Stat3 signaling reduces Stat3-high cell viability and tumorigenicity in vivo.

In the present study, we showed that GBM cells activate a Stat3-dependent upregulation of ODZ1 in the presence of monocytic cells. This activation depends on the secretion of IL-6 by monocytic cells and it can also be induced by fibronectin, a ubiquitous extracellular matrix component. Moreover, we found an active Stat site in the ODZ1 promoter that responds to both stimuli and showed that mutagenesis of this site or blocking interaction of IL-6 with its cognate receptor abrogates transactivation.

**Results**

**Expression of ODZ1 correlates with activation of Stat3.** We have previously described that ODZ1 is induced upon differentiation of stem-like GBM cells in the presence of fetal calf serum (FCS). We first reanalyzed a gene expression array comparing stem-like GBM cells in the absence or presence of FCS and found an increase in the mRNA levels of at least eight genes known to be Stat3 targets including CCND1, SOCS3, CCL2, ADM, THBS1, UGCG, IL1R1 and FOSL1 (Fig. 1a). Stat3 can be phosphorylated and translocated to the nucleus in the presence of FCS but this transcription factor is mostly activated by the cytokine IL-6. Therefore, we explored this in our system by culturing GBM cells in the presence of IL-6 at different time periods (Fig. 1b).
As early as 15 min after exposure to IL-6 there was phosphorylation of Stat3 that further increased by 1 h in the presence of the cytokine. Both FCS and IL-6 upregulated the mRNA levels of ODZ1 in three independent GBM primary cell cultures derived from surgical specimens (Fig. 1c). Moreover, in the presence of FCS addition of IL-6 further increased the expression of ODZ1. In order to confirm that upregulation of ODZ1 was produced through binding of IL-6 to its cognate receptor, we cultured GBM cells in the presence of IL-6 and increasing concentrations of Tocilizumab, an anti-IL-6 receptor antibody that blocked binding to IL-6. The neutralizing antibody efficiently inhibited the IL-6-induced expression of both ODZ1 and the Stat3 target gene CCND1 in a dose-dependent manner (Fig. 1d). Similar results were obtained when cells were treated with increasing concentrations of Ruxolitinib, a Jak-Stat signaling inhibitor used in the clinic (Fig. 1d). Both treatments efficiently inhibited the phosphorylation of Stat3 at the highest concentration (Fig. 1e). Ruxolitinib also significantly reduced the expression of both ODZ1 and CCND1 in response to FCS (Fig. 1f). Since current commercial antibodies against ODZ1 are not suitable for western blotting, at least in our hands, ODZ1 expression was determined at the level of mRNA by quantitative RT-PCR (qPCR).

Fibronectin is a main component of the GBM extracellular matrix and it has been shown to trigger the Stat3 pathway. Thus, we cultured three GBM primary cell lines in fibronectin-coated plates and found an increase in the mRNA levels of ODZ1 (Fig. 2a) and the protein expression of ODZ1 by immunofluorescence (Fig. 2b) that correlated with activation of Stat3 as determined by upregulation of the phosphorylated form of this transcription factor (Fig. 2c). Fibronectin-dependent upregulation of both ODZ1 and CCND1 was blocked by the Jak-Stat inhibitor Ruxolitinib (Fig. 2d). Since ODZ1 is able to function as an invasion factor, we studied the contribution of ODZ1 to the migration of GBM cells in response to fibronectin. In the presence of fibronectin GBM cells...
increased their migration capacity in a Boyden chamber-like assay (Fig. 2e). However, knockdown of ODZ1 by using two ODZ1-specific shRNAs or a mixture of Stat3-specific siRNAs (Fig. 2f) significantly reduced migration of GBM cells in response to fibronectin (Fig. 2e).

**ODZ1 expression is induced in GBM cells by monocytic cells.** GBM tumors are infiltrated by monocytic cells that differentiate to macrophages within the tumor tissue. Monocytes/macrophages are a common source of a number of cytokines, including IL-6. We used a monocytic cell line, U937 in coculture experiments to study the effect of activated monocytes on the expression of ODZ1. First we confirmed that U937 cells secreted quantifiable amounts of IL-6 into the culture medium that were highly increased (about fivefold) following differentiation of U937 towards macrophages in the presence of phorbol diester PMA (Fig. 3a). Moreover, after activation with lipopolysaccharide (LPS), the secreted levels of IL-6 were even higher. Coculture of three different GBM primary cell lines with activated macrophage-like U937 cells induced a high increase (about 3- to 9-fold) in the mRNA levels of ODZ1. Consistent with our previous results, the expression of ODZ1 was drastically reduced in the presence of neutralizing anti-IL-6 receptor antibody (Fig. 3b). The migratory capacity of GBM cells was also explored in this experimental model. LPS-activated U937 increased the migration of GBM cells, that was abrogated when Tocilizumab was added to the culture (Fig. 3c). Similar results in reducing GBM cell migration in the presence of activated U937 were obtained by knocking down the expression of ODZ1 with two different shRNAs (Fig. 3d,e).

In order to explore whether upregulation of ODZ1 in GBM cells was due to activation of Stat3 through monocytic cells, we cocultured activated U937 cells and GBM primary cell lines with or without Ruxolitinib. Following coculture for 48 h, the expression of ODZ1 mRNA was clearly reduced by more than half in all three cell lines treated with the inhibitor (Fig. 4a). The role of Stat3 in ODZ1 gene expression was further confirmed by Figure 3. Monocytic cells promote upregulation of ODZ1 in GBM cells. (a) U937 monocytic cells were incubated in the presence of the differentiation promoter PMA with or without lipopolysaccharide (LPS) as a monocyte/macrophage activator. Supernatant were analyzed 48 h later for the presence of soluble IL-6 by using a specific immunoassay. (b) Expression of ODZ1 mRNA in three GBM cell lines derived from different patients after coculture with activated (LPS-treated) monocytes in the presence or in the absence of 200 ng/ml Tocilizumab (TCZ). (c) Migration assay of GBM1 cells cultured with or without LPS and TCZ. (d) Migration assay of GBM1 cells transfected with two ODZ1-specific shRNAs. (e) Downregulation of ODZ1 mRNA levels in GBM1 cells transfected with ODZ1-specific shRNAs. An irrelevant shRNA (−) was used as negative control. Histograms represent the mean of three independent experiments ± S.D. **p < 0.01.
transfecting GBM cell lines with a splice variant of Stat3 that lacks the transactivation domain and blocks Stat3-mediated gene expression in a dominant negative manner. Blockade of Stat3 activity efficiently downregulated the expression of ODZ1 in all GBM cell lines in the presence of activated U937 cells (Fig. 4b). Moreover, we knocked down Stat3 in GBM cells with a mixture of Stat3-specific siRNAs prior to culture with activated monocytic cells. Downregulation of the protein levels of Stat3 (Fig. 4c) was consistent with a reduction in the expression levels of ODZ1 mRNA (more than 2-fold) and the Stat3 target gene CCND1 (about 2-fold) but not the negative control G6PD (Fig. 4d). Additionally, the migratory capacity of GBM cells was also reduced (Fig. 4e).

The ODZ1 promoter contains a Stat3 site that responds to IL-6 and coculture with U937. We found a Stat consensus site in the ODZ1 promoter about 1 kb from the transcription start site (Fig. 5a). The promoter was cloned into a luciferase reporter vector and the construct was introduced in GBM cells by nucleofection. Consistent with our previous results, culturing GBM cells with FCS activated the ODZ1 promoter (3-fold) after 48 h of exposure (Fig. 5b). Similarly, fibronectin induced a significant activation of the promoter although at a lower level (Fig. 5c). Additionally, the Stat3-activating cytokine IL-6 induced (more than 2-fold) activation of the ODZ1 promoter that was completely abrogated when cells were transfected with the dominant negative variant of Stat3 (Fig. 5d). The specific binding of Stat3 to the ODZ1 promoter was assessed by a chromatin immunoprecipitation assay in cells treated with IL-6. Anti-Stat3-immunoprecipitated DNA was amplified with primers flanking the Stat site and primers flanking a region more than 9 kb further upstream used as a control site (Fig. 5d,e). An amplification signal was only detected in the region containing the Stat site, which was highly reduced (about 4-fold) in the presence of Tocilizumab (Fig. 5e).

To confirm the involvement of the Stat3 consensus site in the activation of the ODZ1 promoter, we changed three key nucleotides of the Stat-binding sequence by site-directed mutagenesis (Fig. 6a). LPS-activated U937 greatly induced promoter activity (7-fold) that was reduced in the presence of the IL-6 receptor blocking antibody, confirming that secretion of IL-6 by monocytic cells is a relevant mechanism for ODZ1 promoter activation (Fig. 6b). Moreover, mutagenesis of the Stat site drastically reduced (2.5-fold) activation of the promoter by...
U937 when GBM cells were transfected with the mutant promoter. This activity was further reduced to a basal (no activation) level in the presence of Tocilizumab (Fig. 6b).

Discussion

We have previously described that ODZ1 is an important factor for GBM cells to invade the surrounding tissue. A key feature of GBM is hypoxia of the tumor core due to the rapid growth of this aggressive glioma, and we showed that hypoxic environments induces the expression of ODZ1 gene by epigenetic modification of its promoter. The complex tumor microenvironment includes extracellular matrix, secreted factors that promote cell signaling and tumor-associated cells. Among these, monocytes/macrophages that infiltrate the tumor constitute a relevant cell population that mediate cell–cell communications with the tumor. Based on this, we argued that some of these microenvironmental interactions may serve to induce the expression of ODZ1, which facilitates GBM cells to invade the neighboring parenchyma. We showed that fetal calf serum, fibronectin and IL-6 were able to upregulate ODZ1 in GBM cells. All these stimuli are known to activate the Jak-Stat transcriptional pathway in tumor cells. Downregulation of this pathway by blocking binding of IL-6 to its cognate receptor or inhibiting Jak kinase activity reduced ODZ1 expression in response to IL-6 but, as expected, only the kinase inhibitor impeded upregulation of ODZ1 in cells incubated with fibronectin or fetal calf serum. Stat3 is a master
regulator of mesenchymal transformation in GBM and it has been described that Stat3 can be constitutively activated in GBM cells, which facilitates tumor growth and regulates the immune microenvironment. We also showed that coculture of GBM cells with IL-6-secreting monocytic U937 cells induces the expression of ODZ1 in GBM cells and their migration, and both are blocked by Tocilizumab, a neutralizing antibody against the IL-6 receptor or knocking down Stat3 expression with specific siRNAs. In line with this, IL-6 has been detected to be abnormally elevated in the cerebrospinal fluid and within the tumor of GBM patients. In cancer, increased levels of IL-6 result in increased activation of Jak-Stat3 pathway, which correlates with poor prognosis. Under this scenario, we searched for Stat3 sites within the ODZ1 promoter and found a Stat consensus sequence about 1 kb from the transcription start site. Moreover, a promoter-containing reporter construct was activated in GBM cells by monocytic U937 cells. Very recently, we described the presence of a CpG site at the 3′ end of the ODZ1 promoter that was hypomethylated in GBM cells. The promoter activity was reduced in response to hypoxia following mutagenesis of the CpG site. Similarly, we mutated the Stat site in the ODZ1 promoter and showed that the response to U937 was drastically reduced. The role of the IL-6-Stat3-ODZ1 axis was further confirmed by using the neutralizing IL-6 receptor antibody which decreased the promoter activity in GBM cells cocultured with U937 cells but also the activity of the mutated promoter. Since no more Stat binding sites have been found in the first 3 kb upstream from the transcription start site of the ODZ1 gene, these data indicate that Stat-independent pathways may have a role in the ODZ1 transcriptional response to IL-6 as it also happens in other biological models. A recent work stratified GBM patients into Stat3-high and Stat3-low cohorts and showed that Stat3 inhibitors were effective in reducing Stat3-high tumor cell viability and tumorigenicity in mouse xenograft models. Interestingly, the use of Stat3 inhibitors also reduced the invasive potential of Stat3-high GBM cells. We previously demonstrated that knockdown of ODZ1 gene expression or removal of the intracellular region of the protein resulted in a drastic reduction of the invasion capacity of GBM cells both in vivo and in vitro. A naturally occurring deletion of the entire ODZ1 gene has been described in primary tumor cells obtained from a GBM patient. These cells were unable to reorganize the cytoskeleton for cell migration after stimulation.

Figure 6. ODZ1 promoter responds to Stat3-activating stimuli. (a) Schematic representation of ODZ1 promoter, indicating the nucleotides within the Stat site changed (bold and underlined) by site-directed mutagenesis. (b) Wild type or mutant ODZ1 promoter were introduced into GBM cells and response of the promoter to the presence of activated U937 cells with or without Tocilizumab (TCZ) was determined by analyzing luciferase activity. Histograms represent the mean of three independent experiments ± S.D. **p < 0.01.
with FCS and maintained a rounded morphology with no or short protrusions\(^2\). Consistently, here we showed that inhibition of Jak-Stat pathway in GBM cells reduces the expression of ODZ1 and promotes cell migration.

Overall, the results presented here show that two key components of GBM microenvironment, fibronectin and IL-6-secreting monocytic cells, induce activation of Stat3 mediated by receptor-associated kinases, typically FAK for the fibronectin receptor\(^2\) and Jak for the IL-6 receptor\(^2\). Activated Stat3 binds to a consensus sequence in the ODZ1 promoter and transactivates ODZ1 gene (Fig. 7). This expression pathway contributes to GBM cell migration and links with our previous mechanistic data about the function of ODZ1\(^2\). Thus, fibronectin/IL-6-Stat3-ODZ1 signaling strengthen current data on the relevance of Stat3 inhibition in GBM patients and highlights potential targets of this pathway. However, ODZ1 which contributes to GBM invasiveness\(^2\), a key feature of this aggressive cancer, is likely to be activated by different transcriptional pathways in response to an array of cell migration stimuli in the microenvironment of GBM cells. Further studies will shed more light on alternative or complementary molecular mechanisms that contribute to the expression of ODZ1.

**Materials and methods**

**Cell cultures.** IDH1/2 wild type primary GBM cell lines used in this study were previously established from surgical specimens in our laboratory\(^2\). Tumor cells were maintained as neurospheres in serum-free DMEM/F12 medium (Invitrogen, Carlsbad, CA, USA) and plated at a density of 3 × 10\(^6\) live cells/60-mm plate. Neurospheres were dissociated every 4–5 days to facilitate cell growth. Cells were used between passages 10 and 20. All cells were confirmed to retain their differentiation capacity, mainly towards astrocytes, reducing the stem cell markers CD133 and Sox2, and increasing the astrocytic marker GFAP as described\(^1\). When indicated, GBM cells were incubated in the presence of 10% fetal calf serum, 50 ng/ml IL-6, 100–400 ng/ml Tocilizumab, 5–30 μM Ruxolitinib or cultured on glass surfaces coated with 10 μg/ml fibronectin (all from Sigma-Aldrich, St Louis, MO, USA). U937 cell line was obtained from ATCC (CRL-1593.2), cultured in RPMI 1640 (Invitrogen) with 10% fetal calf serum and maintained in culture for no more than ten passages after thawing. U937 cells were treated with 200 ng/ml Phorbol 12-myristate 13-acetate (PMA) either alone or with 5 μg/ml lipopolysaccharide (LPS) (both from Sigma-Aldrich). IL-6 secretion by U937 cells was quantified by using an ELISA kit (Quantikine ELISA kit form R&D Systems, Minneapolis, MN, USA).

All cells were tested for mycoplasma using the LookOut Mycoplasma qPCR Detection Kit (Sigma-Aldrich) within one week before the experimental work.
Migration assay. The migratory capacity of GBM cell lines was determined by a modified Boyden chamber assay in 24-well plates (QCM 24-well colorimetric cell migration assay from Merck-Millipore, Darmstadt, Germany). GBM cell lines (500,000 cells) were placed in the upper compartment and following 24 h of incubation under the indicated conditions, cells that have migrated to the lower face of the membrane were fixed and stained according to the manufacturer’s instructions. Migration was determined by measuring absorbance at 560 nm in a spectrophotometer. Whenever indicated, U937 cell line (250,000 cells) were added to the lower compartment whereas GBM cells remained in the upper compartment.

Immunofluorescence staining and analysis. Cells were incubated with antibodies against ODZ1, followed by incubation with fluorescein isothiocyanate-conjugated goat anti-rabbit secondary antibodies (Jackson ImmunoResearch, Cambridgeshire, UK). Nuclei were visualized with 4',6-diamino-2-phenylindole (DAPI) (Life Technologies, Paisley, UK).

Gene expression analyses. The expression of individual genes was evaluated by qPCR on total cellular RNA as previously described. cDNA was generated and amplified using the following primers: β-Actin (5′-GGGGGAAATTCGTCGTTACAT-3′ and 5′-GATGGATGTGAAGTATGTTCT-3′), ODZ1 (5′-ACT CAGAGATGGAATCTCTG-3′ and 5′-CTTATGCAATGTCAAGTG-3′), Stat3 (5′-GGTGGAGAACATT-3′ and 5′-GGTCAACGTGATCAGCT-3′), CCND1 (5′-CAGGATGGAGAAGGAGCAG-3′ and 5′-GGAATTCGAGCAAGAGG-3′) and GAPDH (5′-GCTTATTGCTTCGAG-3′ and 5′-GGTACGACCTACGCTTGGGCAA-3′). qPCR was performed in a 7000-sequence detection system (Life Technologies, Carlsbad, CA, USA).

Analysis of Stat3 target genes differentially expressed between GBM stem-like cells and FCS-treated (differentiated) GBM cells was performed in previous gene expression array data of our group. The selection criteria was based on the fold-change value using a logFC cut-off of 1.5. The array data is deposited in a MIAME compliant database (GEO accession number GSE20736).

Western blot analysis. Total protein from GBM cells were separated on 8% polyacrylamide gels and transferred to nitrocellulose. Blots were incubated with antibodies against pStat3-Ser727 (D8C2Z, Cell Signaling, Danvers, MA, USA), Stat3 (79D7, Cell Signaling) and GAPDH (sc-25778, Santa Cruz Biotechnology. Santa Cruz, CA, USA), followed by secondary anti-rabbit antibodies conjugated to horseradish peroxidase (sc-2357, Santa Cruz Biotechnology). Blots were exposed to X-ray film and bands were quantified by densitometry.

Transfections, gene reporter assays and site-directed mutagenesis. We identified the ODZ1 promoter (Gene ID ENSG0000009694) and amplified a fragment of 1439 bp that included the transcription start site with primers 5′-ATTAGCGGCGCAATGTTGC-3′ and 5′-TGCAGACAATCTCTGGAAGAGG-3′ flanked by KpnI and XhoI sites. The promoter was cloned into KpnI and XhoI sites within the cloning region of the pGL2-luciferase reporter vector (Promega, Madison, WI). GBM cells were cotransfected with 2 μg wild type or mutant promoter constructs, and 0.2 μg pRSET-β-gal by using nucleofection. Transfected cells were cultured for 48 h and cell extracts were prepared and analyzed for the relative luciferase activity by a dual-light reporter gene assay (Applied Biosystems, Foster City, CA). Results were normalized for transfection efficiency with values obtained with pRSET-β-gal. Site-directed mutagenesis of the Stat site in the Stat3 promoter was performed by using the QuickChange site-directed mutagenesis kit (Agilent Technologies, Santa Cruz, CA) with the following primers 5′-GGATGTCTATGATTGTTGCAATATGTTGTAAGAGC-3′ and 5′-GCTTCCTCACCATGTGATTTGCCAAACATCATACGAGC-3′. The modified promoter was sequenced to verify the mutation. When indicated, GBM cells were transfected with a dominant negative variant of Stat3 previously used by our group and others by using nucleofection and gene expression or promoter activity were analyzed after 48 h.

Chromatin immunoprecipitation assay (ChIP). ChIP assay was performed as previously described with some modifications. Briefly, GBM cells were incubated with IL-6 for 24 h with or without Tocilizumab. Following crosslinking and cell lysis, chromatin (10%) was kept as the input control material, the rest was incubated with antibodies against Stat3 (79D7, Cell Signaling) followed by incubation with Protein G Dynabeads (Invitrogen). All samples were treated with RNase A and Proteinase K and purified using ChIP DNA Clean and Concentrator (Zymo Research, Irvine, CA) before amplification. DNA was amplified using primers flanking the Stat site (5′-GTACATGATAGGAGGCCACCA-3′ and 5′-GAACTTTTGGCAACTTGCTT-3′) and primers of a region 9.5 kb upstream from the transcription start site (5′-GAAGCCTCTTTCAAGGAGA-3′ and 5′-GAATGGCTTTGCTATACG-3′) as a negative control. Data were calculated as the percentage of input DNA.

Gene silencing. For ODZ1 knockdown experiments, we used two different shRNAs with sequences 5′-AAT GAGAAATACGAGAAGAGCA-3′ and 5′-AAGACCCACATCTATGGCGACAGA-3′ and a scrambled shRNA (Cat. No. P100042) as a negative control (all from Vigene Biosciences, Rockville, MD). Cells were transfected with shRNAs by nucleofection. Stat3 was silenced by transfecting GBM cells with a mixture of Stat3-specific siRNA (Cat. No. EUH122051) or negative control (Cat. No. EHUEGF) using Lipofectamine RNAiMAX (Invitrogen).
Statistical analysis. All statistics were calculated with the SPSS statistical package (version 13.0). Data are presented as mean ± SD of three independent experiments. Differences between groups were tested for statistical significance using the unpaired 2-tailed Student’s t-test. The significance level was set at p < 0.05.

Received: 10 December 2020; Accepted: 23 July 2021
Published online: 10 August 2021

References
1. Tucker, R. P. & Chiquet-Ehrismann, R. Teneurins: A conserved family of transmembrane proteins involved in intercellular signaling during development. Dev. Biol. 290, 237–245 (2006).
2. Talamillo, A. et al. ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene 36, 1733–1744 (2017).
3. Petriti, I. et al. Whole genome and transcriptome sequencing of a B3 thymoma. PLoS ONE 8, e60572 (2013).
4. Jiang, Z. et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res. 22, 593–601 (2012).
5. Lefranc, F., Le Rhun, E., Kiss, R. & Weller, M. Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets? Cancer Treat Rev. 68, 145–154 (2018).
6. Drappatz, J., Norden, A. D. & Wen, P. Y. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev. Neurother. 9, 519–534 (2009).
7. Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R. & Kettenmann, H. The brain tumor microenvironment. Glia 60, 502–514 (2012).
8. Szulzewsky, F. et al. Human glioblastoma-associated microglia/macrophages express a distinct RNA profile compared to human control and murine samples. Glia 64, 1416–1436 (2016).
9. Bromberg, J. & Darnell, J. E. Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468–2473 (2000).
10. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9, 798–809 (2009).
11. Tan, M. S. Y. et al. STAT3 gene signature stratifies glioma patients for targeted therapy. Nat. Commun. 10, 3601 (2019).
12. Nogueira, L. et al. Blockade of the NFkappaB pathway drives differentiating glioblastoma-initiating cells to senescence both in vitro and in vivo. Oncogene 30, 3357–3358 (2011).
13. Dauer, D. J. et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 24, 3397–3408 (2005).
14. Miyakoshi, M., Yamamoto, M., Tanaka, H. & Ogawa, K. Serine 72 phosphorylation of STAT3: An early change in mouse hematopoietocarcinogenesis induced by neonatal treatment with diethyl nitrosamine. Mol. Carcinog. 53, 67–76 (2014).
15. Kattner, A. S. et al. IL-6 receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A retrospective analysis. Ann. Hematol. 99, 847–853 (2020).
16. Konstandin, M. H. et al. Fibronectin is essential for reparative cardiac progenitor cell response after myocardial infarction. Circ. Res. 113, 115–125 (2013).
17. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F. & Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334(Pt 2), 297–314 (1998).
18. Real, P. J. et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21, 7611–7618 (2002).
19. Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105–115 (1999).
20. Rehimi, R., Bartusel, M., Solinas, F., Altullmer, J. & Rada-Iglesias, A. Chromatin immunoprecipitation (ChIP) protocol for low-abundance embryonic samples. J Vis. Exp. 126, 56186 (2017).

Author contributions
J.L.F.-L.: conceived the study and designed the experimental work; analyzed data; wrote the manuscript. V.V.: performed experimental work and helped with data analysis. O.G.: performed experimental work. A.T.: performed immunofluorescence analyses. C.V.: designed part of the experimental work and helped with data analysis.

Funding
This work was supported by the Instituto de Salud Carlos III through Grant PI17/01399, co-funded by European Regional Development Fund/European Social Fund “A way to make Europe/Investing in your future” and Instituto de Investigación Valdecilla (IDIVAL) (APG/03) to J.L. Fernandez-Luna.

Competing interests
The authors declare no competing interests.
